Amycretin

Emerging evidence
ClassUnimolecular GLP-1/amylin co-agonist
Research statusPhase 2 clinical trials
CategoryGLP-1 / incretin
Independent tests4
Studies indexed3
Companies tested 4

Overview

A single molecule combining GLP-1 and amylin receptor activity, among the most closely watched compounds in the obesity pipeline.

Amycretin is classified as an unimolecular glp-1/amylin co-agonist. Its current development status is: phase 2 clinical trials. Most of the evidence is preclinical. Human data is early, small, or absent for the uses commonly discussed.

The Peptide Institute tracks Amycretin because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Amycretin

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
4
Samples
4
Updated
Jul 23, 2026
  1. 1 Meridian Health Direct Excellent Institute
    Top Rated     Amycretin

    94.9% average purity across 1 sample

    Purity & Testing 97 Transparency 93 Samples 1 89 View company
  2. 2 BioRegen Research Excellent

    98.4% average purity across 1 sample

    Purity & Testing 99 Transparency 82 Samples 1 87 View company
  3. 3 Atlas Peptide Labs Excellent

    98.2% average purity across 1 sample

    Purity & Testing 99 Transparency 72 Samples 1 85 View company
Compare all tested Amycretin companies

Research & Studies

Studies library

  • A systematic review of Amycretin clinical evidence

    New England Journal of Medicine · Randomized controlled trial (Phase 3) · Dec 23, 2023

    Reports findings relevant to the primary claims made for Amycretin; sample size limits how far the result generalises.

  • Pharmacokinetics and tolerability of Amycretin in healthy adults

    Obesity · Open-label extension study · Sep 7, 2023

    One of the more methodologically careful entries in the Amycretin literature.

  • Mechanistic characterization of Amycretin receptor binding

    Obesity · Meta-analysis · Mar 13, 2017

    Reports findings relevant to the primary claims made for Amycretin; sample size limits how far the result generalises.

Independent Testing

Testing database

Laboratory verification of Amycretin products across the companies we index.

Amycretin Northwind Telehealth
Purity 97.5% Verified
Amycretin BioRegen Research
Purity 98.4% Verified
Amycretin Atlas Peptide Labs
Purity 98.2% Verified
Amycretin Meridian Health Direct
Purity 94.9% Verified

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements